<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01534312</url>
  </required_header>
  <id_info>
    <org_study_id>CGMP in UC</org_study_id>
    <nct_id>NCT01534312</nct_id>
  </id_info>
  <brief_title>Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)</brief_title>
  <official_title>Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Casein glycomacropeptide (CGMP) has anti-inflammatory properties in experimental rodent
      colitis and using human in vitro inflammation models. Its use as a food ingredient has proven
      safe and with no influence on dietary intake. We hypothesize that orally administered CGMP
      has a beneficial effect comparable to that of mesalazine in active distal ulcerative colitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GCMP has mainly been used as food additive in patients with specific dietary needs, i.e. in
      infant formulas, adipositas, or in patient with phenylketonuria. Due to its antiinflammatory
      properties we hypothesize that it may be used alone or along with conventional therapy in
      inflammatory diseases such as ulcerative colitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fecal calprotectin reduction</measure>
    <time_frame>4 weeks</time_frame>
    <description>Relative reduction in fecal calprotectin measured before and after 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical activity index</measure>
    <time_frame>4 weeks</time_frame>
    <description>Simple Clinical Colitis Index, range 0-20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>4 weeks</time_frame>
    <description>Quality of life measured yb Short Health Scale (4 items ranged 0-10, total range 0-40)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endoscopic Mayo score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Grade of inflammation (range 0-3) in rectum according to Mayo score, visually judged during endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serial fecal calprotectin</measure>
    <time_frame>8 weeks</time_frame>
    <description>fecal calprotectin week 0-4-6-8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>CGMP protein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Casein glycomacropeptide 30 gram/day, unchanged prophylactic 5ASA dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard oral 5ASA maximal dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Increase from prophylactic dose 5ASA (mesalazine) to maximal oral dose, i.e. 4800 grams of mesalazine (Asacol/Mezavant)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGMP protein</intervention_name>
    <description>Casein glycomacropeptide purified powder dissolved in 300 ML water once daily</description>
    <arm_group_label>CGMP protein</arm_group_label>
    <other_name>Casein glycomacropeptide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maximal oral 5ASA</intervention_name>
    <description>4800 grams/day of Mesalazine (Asacol/Mezavant)</description>
    <arm_group_label>Standard oral 5ASA maximal dose</arm_group_label>
    <other_name>Asacol</other_name>
    <other_name>Mezavant</other_name>
    <other_name>Mesalazine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or more

          -  Diagnosed ulcerative colitis

          -  Signs of clinical activity with SCCAI of 3 or more

          -  Extension more than 10 cm and no more than 40 cm from anus

        Exclusion Criteria:

          -  Rectal temperature more than 38 degrees Celcius

          -  Diagnosed celiac disease or lactose intolerance

          -  Unable to speak or understand Danish

          -  Prior biologics or systemic steroids 4 weeks up to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik Vilstrup, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Professor, University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of medicine V (Hepatology and Gastroenterology)</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2012</study_first_posted>
  <last_update_submitted>November 20, 2016</last_update_submitted>
  <last_update_submitted_qc>November 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glycopeptides</keyword>
  <keyword>Dietary proteins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caseins</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

